YD Bio enters into binding LOI to acquire shares, assets of SSMC

YD Bio (YDES)announced it has entered into a binding Letter of Intent, LOI, to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology, SSMC. The LoI, executed on January 20, 2026, signifies a definitive step towards integrating SSMC’s advanced immunocell therapy capabilities into YD Bio Ltd’s strategic portfolio, further solidifying the Company’s strategic transformation from a portfolio of assets to an end-to-end biotechnology ecosystem. Under the terms of the LoI, YD Bio Ltd intends to acquire 100% of the equity interests of Safe Save Cell Holdings, an offshore holding company to be established through a SSMC’s corporate restructuring that will result in the KY Company holding 100% of SSMC’s shares, for a total consideration of NT$839,832,000, or US$26.87M